patent.fyi
Applications  /  US 2026/0355314
United States Patent Application Publication

US 2026/0355314 A1

Published
Nov 12, 2026
Filed
Dec 18, 2023
Earliest date on the face
Dec 16, 2022
Classification
A61K 40/22
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Selection before organ implantation

What ifWhat if patient selection takes place before the patient receives the organ?
Claim language“having a transplanted organ”

The transplant team selects a kidney transplant candidate with an identified living donor and a negative donor crossmatch. The team plans the organ transplant and donor cell collection together so that the cell infusion can take place in the same transplant admission.

1.2Kidney from an identical twin

What ifWhat if the transplanted kidney comes from the recipient’s genetically identical twin?
Claim language“not genetically identical to the patient”

A panel of polymorphic DNA markers confirms that the donor and recipient are monozygotic twins. The twins share inherited tissue antigens, which reduces the stimulus for an immune response against the kidney. Serum creatinine and urine protein measurements track graft function.

1.3Drug dependent rejection control

What ifWhat if the immunosuppressive agent controls rejection through continued dosing while donor directed tolerance is assessed separately?
Claim language“facilitates immunological tolerance”

A calcineurin inhibitor reduces T-cell activation while the patient receives maintenance therapy. Whole-blood trough measurements guide dosing, and graft function and biopsy findings inform assessment of any later reduction in drug exposure.

1.4Antibody against a lymphocyte marker

What ifWhat if the conditioning regimen uses a monoclonal antibody directed against the cell surface protein CD52 for lymphocyte depletion?
Claim language“rabbit anti-thymocyte globulin”

The antibody binds CD52 on mature T and B cells and promotes their clearance through complement and immune effector cells. Peripheral blood lymphocyte counts track depletion and recovery.

1.4Drug based marrow conditioning

What ifWhat if the conditioning regimen uses low intensity chemotherapy to support donor cell engraftment?
Claim language“total lymphoid irradiation”

A reduced-intensity regimen combines a purine analog that suppresses host lymphocytes with an alkylating agent that reduces host marrow cell populations. Donor and recipient DNA markers in blood cells measure the contribution of donor cells after infusion.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Delayed tolerance in veterinary transplantation

A veterinary transplant service uses the delayed sequence in a feline recipient with a functioning kidney graft and ongoing immunosuppression. The kidney donor record links the recipient to the same cat for later collection of hematopoietic stem and progenitor cells and T cells. A veterinary hematology laboratory identifies the cell populations with feline-reactive reagents, and the transplant service uses species-specific conditioning before infusing the cells.

Component substitution

Marrow replaces mobilized peripheral blood

Bone marrow aspirate from the original organ donor replaces mobilized peripheral blood as the source of hematopoietic stem and progenitor cells. The processing laboratory filters the aspirate and enriches its CD34-positive fraction by immunomagnetic selection. A separately collected peripheral blood fraction from the same donor supplies T cells, and the two fractions are counted and released for infusion after recipient conditioning.

Parameter or scale variation

Conditioning twelve months after organ transplantation

The transplant date starts a 12-month interval before the recipient enters conditioning. The transplant team checks graft function against the recipient's established baseline at months 9 and 12 and reviews the ongoing immunosuppressive regimen at both visits. At month 12, recipients who meet the program's stability criteria proceed to conditioning and subsequent infusion of hematopoietic stem and progenitor cells and T cells from the original donor.

Combination with existing systems

Cryogenic banking at the organ transplant

A cell therapy bank receives hematopoietic stem and progenitor cells and T cells collected from the original donor at the time of organ transplantation. The bank cryopreserves the two fractions in separate containers and links both container identifiers to the organ donor record. When the recipient enters the delayed conditioning program, the bank verifies the donor link and releases both fractions for thawing and infusion.

Biopsy review before delayed conditioning

A transplant pathology system links a preconditioning graft biopsy to the recipient and displays it alongside archived specimens from the same graft. The pathologist records evidence of active rejection and the extent of chronic tissue injury in structured fields. The transplant team uses those results and current graft function to determine readiness for conditioning and subsequent infusion of cells from the original donor.

Automated or data-driven variant

Barcode verification of donor cell identity

A barcode system links the original organ donor identifier, the recipient identifier and the identifiers on both cell fractions. At the bedside, staff scan the recipient wristband and each container, and software checks both container records against the donor recorded for the transplanted organ. The application records successful checks and blocks electronic infusion sign-off when a code is unreadable or the identifiers disagree.

Specific version of a part

Progenitor enriched donor cell infusion

Immunomagnetic selection retains cells that express CD34 and removes most mature T cells from the donor collection. The selected progenitors support blood cell production after engraftment, and flow cytometry quantifies residual T cells in the infusion.

Selection of stable kidney recipients

Serial serum creatinine and urine protein measurements establish a baseline for a recipient with a functioning kidney graft. A graft biopsy assesses active rejection and chronic tissue injury before conditioning.

Trough guided calcineurin inhibition

The recipient takes an oral calcineurin inhibitor on a fixed daily schedule. A whole-blood sample drawn immediately before the next dose measures the trough concentration, which guides dose adjustments during maintenance therapy.

Fractionated lymphoid irradiation with antibody

An external beam plan covers major lymph node regions and the spleen in multiple fractions and accounts for dose to adjacent organs. Intravenous rabbit anti-thymocyte globulin depletes circulating T cells during conditioning.

Measured donor cell fractions

A peripheral blood collection from the original organ donor supplies a CD34-enriched progenitor fraction and a separate T-cell fraction. Flow cytometry measures viable CD34-positive and CD3-positive cells so that each fraction can be administered by cell count per kilogram of recipient body weight.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0076731 A1
Published
Mar 27, 2008
Filed
Apr 13, 2007
Class
A61K 48/00
Document BUS 2010/0184732 A1
Published
Jul 22, 2010
Filed
Nov 18, 2009
Class
A61K 31/573
Claim 1
Document A
Document B
1.1(a) selecting a patient having a transplanted organ, wherein:
Another embodiment of the invention provides methods for decreasing rejection of a bone marrow allograft, or rejection of a solid organ allograft or xenograft in a patient by administering a substance that inhibits SHIP function.
A · US 2008/0076731 A1 · ¶ 25
In another embodiment, the TAC is administered to patients having undergone hematopoietic cell or organ allograft transplantation, i.e. allogenic hematopoietic cell recipients who have typically received marrow-ablative chemotherapy and/or total body irradiation followed by donor hematopoietic cell infusion, or patients having undergone intestinal or liver transplantation.
B · US 2010/0184732 A1 · ¶ 29
1.2the transplanted organ is obtained from an individual who is not genetically identical to the patient; and
Another embodiment of the invention provides methods for decreasing rejection of a bone marrow allograft, or rejection of a solid organ allograft or xenograft in a patient by administering a substance that inhibits SHIP function.
A · US 2008/0076731 A1 · ¶ 25
HVGD disease may occur, for example, when a donor intestine is transplanted into a patient with a diseased intestine. In this case, cells of the patient's immune system (the host) may attack the foreign intestinal tissue (the graft).
B · US 2010/0184732 A1 · ¶ 7
1.3the patent is being or has been administrated an immunosuppressive agent that facilitates immunological tolerance of the transplanted organ;
A method of long-term therapy using corticosteroids to treat tissue damage associated with graft-versus-host disease in a patient having undergone hematopoietic cell transplantation, and host-versus-graft disease in a patient having undergone organ allograft transplantation.
B · US 2010/0184732 A1 · abstract
1.4(b) performing a transplantation conditioning regimen on the patient, wherein the transplantation conditioning regimen comprises the administration of rabbit anti-thymocyte globulin and total lymphoid irradiation; and
In another embodiment, the TAC is administered to patients having undergone hematopoietic cell or organ allograft transplantation, i.e. allogenic hematopoietic cell recipients who have typically received marrow-ablative chemotherapy and/or total body irradiation followed by donor hematopoietic cell infusion, or patients having undergone intestinal or liver transplantation.
B · US 2010/0184732 A1 · ¶ 29
1.5(c) transfusing the patient with donor hematopoietic stem/progenitor cells and T cells; wherein the donor hematopoietic stem/progenitor and T cells are obtained from the individual from which the transplanted organ was obtained.
Whole bone marrow (WBM) cells are obtained from tibias and femurs of A/SW-(H-2s)/Sn (H-2s), BALB/C(H-2d) or β2m−/− donor mice and washed once in PBS. WBM cells (5×106) are injected intravenously into lethally irradiated hosts (950 Rad).
A · US 2008/0076731 A1 · ¶ 115
In another embodiment, the TAC is administered to patients having undergone hematopoietic cell or organ allograft transplantation, i.e. allogenic hematopoietic cell recipients who have typically received marrow-ablative chemotherapy and/or total body irradiation followed by donor hematopoietic cell infusion, or patients having undergone intestinal or liver transplantation.
B · US 2010/0184732 A1 · ¶ 29

An empty cell means only that no passage was reproduced there.

Statements in these documents
Specifically, genetic and pharmaceutical methods are disclosed for the modulation of SHIP activity in order to influence NK cell function.
A · US 2008/0076731 A1 · ¶ 3
The invention further relates to methods for decreasing immune rejection of histo-incompatible bone marrow grafts and solid organ allografts or xenografts, and methods for screening substances or genetic constructs for their ability to modulate SHIP activity.
A · US 2008/0076731 A1 · ¶ 3
This study did, however, provide evidence that oral BDP therapy was safe and effective in the treatment of mild-to-moderate intestinal GVHD, taken alone or when added to prednisone.
B · US 2010/0184732 A1 · ¶ 6
While significant advances have been made with regard to the treatment of GVHD following bone marrow transplantation, there is still a need in the art for improved methods, particularly in the context of preventing the intestinal mucosal damage associated with the onset of GVHD.
B · US 2010/0184732 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355314 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355314/, SHA-256 19c87c1b27d5da466876b70736e623c5f9bd37a1eda7325e4f2eba59f5d18f6f
First published
Permanent addresshttps://patent.fyi/US20260355314/
Content fingerprint (SHA-256)19c87c1b27d5da466876b70736e623c5f9bd37a1eda7325e4f2eba59f5d18f6f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi